ストックスクリーナーアプリを入手
12.79
0.39%
-0.05
アフターアワーズ：
12.80
0.01
+0.08%
Climb Bio Inc (CLYM) 最新ニュース
Climb Bio Inc (CLYM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CLYM Maintained by Wedbush -- Price Target Raised to $20.00 - GuruFocus
Wedbush Raises Price Target on Climb Bio to $20 From $17, Keeps Outperform Rating - Moomoo
Climb Bio Inc (CLYM) Cash Flow - TradingKey
Climb Bio Inc (CLYM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Climb Bio Inc (CLYM) Institutional Confidence - TradingKey
Climb Bio Inc (CLYM) Valuation: PE, PB & Fair Value Analysis - TradingKey
CLYM|Climb Bio Inc|Price:12.840|Chg%:+0.080 - TradingKey
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility (CLYM) - Seeking Alpha
Frontier tech research, news & data - MLQ.ai
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
FMR LLC's Strategic Acquisition of Climb Bio Inc Shares - GuruFocus
Q32 Bio Shares Climb Ahead of Drug Trial Results for Alopecia Treatment - Moomoo
Climb Bio Inc. (CLYM) Edges Lower Amid Mixed Biotech Sentiment, Key Support Levels in FocusWeak Sell Signals - DonanımHaber
Climb Bio Inc. (CLYM) Q1 2026 Earnings: Smaller-Than-Expected Loss Signals Cost DisciplineNegative Surprise Momentum - dars.gov.et
Climb Bio, Inc. advances CD19-based approach to preserve protective antibody function - Traders Union
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Yahoo Finance
CLYM Q1 2026 Earnings: Narrower Loss than Expected, Stock Edges HigherPost-Announcement Reaction - DonanımHaber
Form 13D/A Climb Bio For: 7 July By Investing.com - Investing.com Nigeria
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses? - RTTNews
Climb Bio Inc. (CLYM) Q1 2026 Earnings: EPS Beat Partially Offsets Market Skepticism as Pre-Revenue Biotech Navigates Clinical ProgressDividend Earnings Report - dars.gov.et
Climb Bio Appoints Breanna O’Reilly to Board - The Globe and Mail
Climb Bio, Inc. Files Form 8-K: Key Company Information, NASDAQ Listing, and Emerging Growth Status - Minichart
Form 4 Climb Bio Inc For: 1 July By Investing.com - Investing.com UK
70,284 Climb Bio (CLYM) share options granted for RA Capital-related funds - Stock Titan
Climb Bio (CLYM) director receives 70,284 stock options tied to RA Capital funds - Stock Titan
Climb Bio (CLYM) director Breanna Maurine Celebi files initial Form 3 - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Climb Bio, Inc. reveals on-target clinical results for budoprutug in new study - Traders Union
Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing - marketscreener.com
Form 4 Climb Bio Inc For: 30 June By Investing.com - Investing.com Canada
Form 144 CLIMB BIO For: 30 June By Investing.com - Investing.com Nigeria
Climb Bio CEO Aoife Brennan sells $406,979 in shares By Investing.com - Investing.com India
Climb Bio (CLYM) CEO sells 30,902 shares after RSU vesting - Stock Titan
[144] Climb Bio, Inc. SEC Filing - Stock Titan
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2500 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Value Benchmark - marketscreener.com
Climb Bio, Inc. advances rare kidney disease collaboration with patient-centered approach - Traders Union
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000E Growth Benchmark - marketscreener.com
CLYM Q1 2026 Earnings: Narrowed Loss Beat Expectations as Biotech Continues Pipeline DevelopmentProfit Margin Analysis - dars.gov.et
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Dynamic Index - marketscreener.com
CLYM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineEarnings Expansion Phase - dars.gov.et
Climb Bio Q1 2026 Earnings: Bottom-Line Beat Provides Positive MomentumEPS Surprise History - dars.gov.et
Why is Climb Bio stock gaining Friday? - MSN
Price to sales forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to earnings forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to book forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Climb Bio, Inc. Actuals & Estimates (NASDAQ:CLYM) - TradingView
NephCure Patient and Youth Summits partnership expands support for rare kidney disease patients - Traders Union
Raymond James Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
S&P 500 Futures Climb in Premarket Trading; Bio-Techne, Micron Technology Lead - Barron's
Climb Bio stock price target reiterated at $20 by H.C. Wainwright - Investing.com UK
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):